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Abstract: Antibiotic resistance is one of the main public health concerns of this century. This
resistance is also associated with oxidative stress, which could contribute to the selection of resistant
bacterial strains. Bearing this in mind, and considering that flavonoid compounds are well known for
displaying both activities, we investigated a series of hydroxy-3-arylcoumarins with structural features
of flavonoids for their antibacterial activity against different bacterial strains. Active compounds
showed selectivity against the studied Gram-positive bacteria compared to Gram-negative bacteria.
5,7-Dihydroxy-3-phenylcoumarin (compound 8) displayed the best antibacterial activity against
Staphylococcus aureus and Bacillus cereus with minimum inhibitory concentrations (MICs) of 11 µg/mL,
followed by Staphylococcus aureus (MRSA strain) and Listeria monocytogenes with MICs of 22 and
44µg/mL, respectively. Moreover, molecular docking studies performed on the most active compounds
against Staphylococcus aureus tyrosyl-tRNA synthetase and topoisomerase II DNA gyrase revealed
the potential binding mode of the ligands to the site of the appropriate targets. Preliminary
structure–activity relationship studies showed that the antibacterial activity can be modulated by the
presence of the 3-phenyl ring and by the position of the hydroxyl groups at the coumarin scaffold.
Keywords: hydroxy-3-arylcoumarins; Perkin–Oglialoro reaction; antibacterial activity;
molecular docking
1. Introduction
Antibiotic resistance is one of the leading public health concerns of this century [1,2], mainly due
to the emergence, spread, and persistence of multidrug-resistant (MDR) bacteria, informally named as
“superbugs”, which cause infections that fail to respond to conventional treatments. The increasingly
widespread use and misuse of antibiotics in animals and humans, as well as the lack of innovation in
antibiotic research (decline in the number of new antibiotic classes), are among the leading causes of
the development and spread of antimicrobial resistance [3]. Policies to control the inappropriate and
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irrational use of antibiotics are urgently needed, as is the development of new chemical entities as
antibacterial agents [4].
A group of MDR bacteria collectively known as “ESKAPE”, which includes Gram-positive and
Gram-negative species (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), are frequently isolated in hospital
environments, where they are responsible for the majority of nosocomial infections [5]. In particular,
Gram-positive bacteria have predominantly developed resistance to all the available antibiotics and
pose a serious problem not only in hospitals but also for the general population [6,7]. Infections of
methicillin-resistant Staphylococcus aureus (MRSA) are of particular concern [8].
Several recent reports associate antibiotic resistance with oxidative stress [9,10]. Therefore,
molecules presenting dual activity as antibacterial and antioxidant can be attractive candidates [9].
Tyrosyl-tRNA synthetase represents an attractive target enzyme for finding new antibacterial
agents [11]. It belongs to the aminoacyl-tRNA synthetases (aaRSs) and is responsible for catalyzing
the covalent binding of amino acids to their respective tRNA to form charged tRNA. Thus, inhibition
of aaRSs affects cell growth due to their key role in the protein biosynthesis process. Topoisomerase
II DNA gyrase is another target enzyme, and coumarins have proven to be one of the most studied
families of inhibitors of this enzyme [12]. DNA topoisomerases catalyze changes in the topology of
DNA and are essential for cell survival. DNA gyrase is a type II topoisomerase that can introduce
negative supercoils into DNA by ATP consumption. It is essential in all bacteria but is absent from
higher eukaryotes, making it an attractive target for antibacterial agents [13].
Coumarins represent an important family of naturally occurring and/or synthetic compounds that
are well known for their pharmacological activities [14,15]. 4-Arylcoumarins or neoflavones, shown
in Figure 1, are examples of naturally occurring flavonoids [16] with antioxidant and antibacterial
activities [17,18].
Figure 1. Chemical structure of some flavonoids and a flavonoid analogue (3-arylcoumarin).
Matos et al. have already reported some simple coumarins and 3-phenylcoumarins as interesting
antibacterial agents for human use, in particular against clinical isolates of S. aureus [19,20]. The
3-(3′-methylphenyl)-6-nitrocoumarin proved to be the best compound of that series, presenting a
minimum inhibitory concentration (MIC) for S. aureus of 8 µg/mL.
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Taking this into account, we investigated a series of 3-arylcoumarins with structural features of
flavonoids and evaluated their antibacterial and antioxidant activity. The aim of our work was to
understand how the structural modification of these compounds could affect the biological activities.
For the current study, different chemical features were explored in order to increase the chemical
space and the potential interaction profile with the targets.
Herein, a series of 3-arylcoumarins were synthesized and evaluated against four Gram-positive
and three Gram-negative strains. Moreover, their antioxidant properties were considered. Molecular
docking studies using tyrosyl-tRNA synthetase and topoisomerase II DNA gyrase from S. aureus were
also performed to better understand the mechanism of action of these molecules.
2. Results and Discussion
Compounds 2–10 are known and were synthesized via a two-step Perkin–Oglialoro reaction
(Scheme 1). Different commercially available ortho-hydroxybenzaldehydes and aryl/heteroarylacetic
acids were condensed in the presence of potassium acetate (CH3CO2K) in acetic anhydride (Ac2O)
under reflux for 16 h to afford the acetoxy-3-aryl/heteroarylcoumarins. This step involves sequential
acetylation of the hydroxyl groups and pyrone ring closure in a single-pot operation. Further on, the
hydrolysis of the obtained acetoxy derivatives, in the presence of aqueous hydrochloric acid (HCl) and
methanol (MeOH) under reflux for 3 h, afforded the hydroxyl substituted 3-aryl/heteroarylcoumarins
2–10. Compound 1 (daphnetin) is commercially available from Sigma-Aldrich.
Scheme 1. Synthetic routes and chemical structures of compounds 1–10.
The synthesized compounds were screened for antibacterial activity against different bacterial
strains, including both Gram-positive and Gram-negative bacteria, and the results are reported in
Table 1.
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Table 1. Antibacterial activity of hydroxy-3-arylcoumarins against Gram-positive (A) and
Gram-negative (B) bacterial strains. Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) values are expressed in µg/mL.
Compounds









MIC MBC MIC MBC MIC MBC MIC MBC
1 500 >500 500 >500 500 >500 500 >500
2 62.5 250 62.5 250 125 500 15.6 62.5
3 62.5 500 125 500 250 >500 62.5 250
4 125 500 250 >500 250 >500 62.5 250
5 125 500 125 500 250 >500 125 250
6 500 >500 500 >500 500 >500 250 500
7 >500 n.d >500 n.d >500 n.d >500 n.d
8 11 87.5 22 87.5 44 350 11 44
9 >500 n.d >500 n.d >500 n.d >500 n.d
10 >500 n.d >500 n.d >500 n.d >500 n.d
Ampicillin a 2.5 - 10 - 5 - 10 -
Compounds







MIC MBC MIC MBC MIC MBC
1 500 >500 500 >500 >500 n.d
2 500 >500 >500 n.d >500 n.d
3 >500 n.d >500 n.d >500 n.d
4 >500 n.d >500 n.d >500 n.d
5 >500 >500 >500 >500 >500 n.d
6 500 >500 500 >500 >500 n.d
7 >500 n.d >500 n.d >500 n.d
8 >350 n.d >350 n.d >350 n.d
9 >500 n.d >500 n.d >500 n.d
10 >500 n.d >500 n.d >500 n.d
Gentamicin a 5 - 5 - 5 -
a Positive control. n.d: not determined.
Gram-negative bacteria proved to be the less sensitive strains, being resistant to all the compounds
at the maximum tested concentrations (500/350 µg/mL).
The lack of activity or the lower susceptibility of the Gram-negative versus Gram-positive bacteria
may be due to the variation in their cell wall structure. In fact, Gram-negative bacteria possess an outer
lipidic membrane that restricts the access to the periplasm by acting as efficient selective permeation
barrier [21].
Compounds 2–5 and 8 were found to exhibit antibacterial activity against Gram-positive bacteria
but to different extents. Compound 8 was the most active, followed by compound 2, which showed
an interesting effect against L. monocytogenes (MIC = 125 µg/mL) and presented a slightly better
activity against the two S. aureus strains tested (both MICs = 62.5 µg/mL). The highest activity of
compound 2 was detected against B. cereus, with a remarkable MIC of 15.6 µg/mL. A similar activity
was obtained for compound 8 against B. cereus, with a MIC of 11 µg/mL. This compound also showed
the highest antibacterial potential against L. monocytogenes (MIC = 44 µg/mL), S. aureus ATCC 25923
(MIC = 11 µg/mL), and MRSA TN2A strain (MIC = 22 µg/mL). These MIC values are comparable
with those observed in previous studies describing the antibacterial activity of coumarin derivatives
against Gram-positive bacteria, including S. aureus [22–24]. Members of this species are considered
opportunistic pathogens responsible for a broad spectrum of diseases ranging from superficial skin
infections to systemic infections, with the ability to acquire resistance to any antibiotic [25].
An in-depth analysis of structure–activity relationship was performed and indicated that the
simultaneous presence of a phenyl ring at position 3 and two hydroxy groups at positions 5 and 7 of
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the coumarin scaffold (compound 8) improved the antibacterial activity of the coumarin derivatives. In
fact, compound 1 (7,8-dihydroxycoumarin), which does not have any aromatic substituent at position 3
of the coumarin ring and is the simplest compound of the series, did not exert any antibacterial activity
at the highest tested concentration (500 µg/mL). The same results were obtained for compounds 6 and
7, which differed from compound 1 on the presence of a thiophenyl ring at position 3 of the coumarin
structure (Scheme 1). Also, all the studied 3-phenyl derivatives (compounds 2–5) were found to be
active, with compound 2 the most active among them, followed by 4 and 3, while compound 5 was
the least active from this group. Considering the structure of the compounds within this series, it
seems that the presence of hydroxyl groups on the 3-phenyl ring decreases the antibacterial activities.
The presence of two hydroxyl groups on the fused benzo ring of the coumarin scaffold and the
contemporary presence of a phenyl ring at position 3 (compounds 2–5 and 8) seems to be essential
for antibacterial activity. Compounds 9 and 10 with a single hydroxyl group exhibited no activity
when compared to the dihydroxycoumarin derivative 8. To further elucidate the importance of the
hydroxyl group substitutions in the phenyl ring, compound 8 was tested, and it proved to be the best
compound of the studied series. Thus, the two hydroxyl groups at positions 5 and 7 of the coumarin
ring increased the antibacterial activities. These positions can be further studied in order to optimize
the profile of this compound as antibacterial.
Some examples have been reported of compounds combining in one single structure with both
antioxidant and antibacterial activities as two synergistic properties [9]. Taking this into account, the
most active compounds were evaluated for their antioxidant properties. The results are shown in
Table 2.
Table 2. Antioxidant activity of the most active compounds evaluated by the ABTS scavenging method.
Compounds EC50 (µM)
2 ˆ 11.59 ± 0.39 a
3 17.42 ± 0.42 b
4 23.05 ± 0.43 c
5 4.40 ± 0.07 d
8 ˆ 7.08 ± 0.04 e
Trolox $ 13.0 ± 1.1 a
The data are given as mean ± standard deviation (SD) of triplicate experiments. ˆ Data previously described in
reference [26]. $ Positive control. Different letters denote statistically significant differences between compounds
(p < 0.001).
All the studied compounds had redox properties, which would allow them to act as antioxidants.
Among them, compound 2 showed antioxidant activity comparable to Trolox, and compounds 5 and 8
had EC50 values significantly better than that of the positive control.
These results led us to consider compound 8 as a promising compound with dual antibacterial
and antioxidant activity and therefore as a potential candidate to serve as an antibiotic.
The molecular properties of the most active compounds, namely, the dihydroxy-substituted
derivatives 2 and 8 as well as 9, which contains only one hydroxyl group, were predicted using
Swiss-ADME web server [27] against the known antibiotic, ampicillin (Table 3).
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Table 3. Molecular properties of the molecules under study. (A) Physicochemical properties and
(B) pharmacokinetics.
A. Physicochemical Properties
Compounds 2 and 8 9 Ampicillin
Molecular Formula C15H10O4 C15H10O3 C16H19N3O4S
Molecular Weight (g/mol) 254.24 238.24 349.40
Rotatable bonds 1 1 5
H-bond acceptor atoms 4 3 5
H-bond donor atoms 2 1 3
Molar refractivity 71.97 69.94 92.56
Polar Surface area 70.67 50.44 138.03
Lipophilicity (consensus) 2.46 2.91 0.08
Water solubility Soluble Soluble Very soluble
B. Pharmacokinetics
Gastrointestinal absorption High High Low
Blood–brain barrier permeation Yes Yes No
P-glycoprotein substrate No No No
Cytochrome P450 1A2 inhibitor Yes Yes No
Cytochrome P450 2D6 inhibitor No No No
Cytochrome P450 3A4 inhibitor No No No
Druglikeness (Lipinski rule) Yes Yes Yes
Compounds 2 and 8 shared similar physicochemical and pharmacokinetic properties as they had
an identical number of atoms and differed only in the hydroxyl group position within the coumarin
scaffold. On the other hand, compound 9 lacked one hydroxyl group compared to compounds 2 and 8.
This difference was reflected in the lower value of polar surface area and in the number of hydrogen
bond acceptor and donor atoms. The coumarin-derived compounds were less flexible with respect
to ampicillin, evident from a lower number of rotatable bonds. Furthermore, compounds 2, 8, and 9
displayed high gastrointestinal absorption (GA) and blood–brain barrier (BBA) permeation properties,
which are absent in ampicillin. All the molecules exhibited druglikeness characteristics according to
Lipinski rules.
Molecular docking of compounds 2, 8, and 9 and ampicillin was performed to identify the binding
sites on the structure of S. aureus tyrosyl-tRNA synthetase (Figure 2) and topoisomerase II DNA gyrase
(Figure 3) proteins. Redocking of the cocrystal ligands was performed to validate the docking protocol.
We found variation between 1 and 2 Å for the root mean square deviation (RMSD) values and a
conserved binding pattern (Figure S1, Supplementary Materials).
Docking results against S. aureus tyrosyl-tRNA synthetase protein indicated a well-conserved
binding region but with slightly different predicted best binding energy values. The best free binding
energy was found for compound 8 (−9.2 kcal/mol), followed by compound 2 (−9.0 kcal/mol), and the
lowest value was for compound 9 (−8.5 kcal/mol). In comparison to the other investigated compounds,
ampicillin (reference molecule) displayed favorable binding energy value by ~2 kcal/mol. This aspect
was consistent with a higher number of interactions noted for the ampicillin complex. The observed
trend in the binding free energy was found to be consistent with the experimental inhibition trend for
the molecules.
A very similar value of binding free energy (~7.0 kcal/mol) was found for compounds 2, 8, and 9
against topoisomerase II DNA gyrase. In all the investigated systems, we found aromatic–aromatic
interactions involving the bases of DNA and the ligand. We noted significant changes in the
ligand–receptor interaction network between the molecular systems. Compounds 2 and 8 displayed
a higher number of hydrogen bond interactions and aromatic–aromatic interactions with respect
to compound 9. Furthermore, we found pi–cation interactions involving residue Arg-1122 only for
compound 8 and ampicillin.
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Figure 2. Interaction network between S. aureus tyrosyl-tRNA synthetase protein and the studied
compounds. The negatively charged residues are shown in red, polar residues in cyan, and hydrophobic
residues in parrot green. Hydrogen bond (H-bond) interactions are shown as pink arrow.
Figure 3. Interaction network between topoisomerase II DNA gyrase and the studied compounds. The
protein residues with a negative charge are shown in red, positive charge in velvet, polar in cyan, and
hydrophobic in parrot green. The DNA bases are shown in grey. The H-bond interactions are shown as
pink arrow, pi–pi stacking as green line, and pi–cation as red line.
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3. Materials and Methods
3.1. Chemistry
Compound 1 was obtained from Sigma-Aldrich (St Louis, Missouri, USA) and derivatives 2–10,
which are known, were prepared as described below and their purity determined by elemental (CHN)
analysis. The NMR (1H and 13C) and mass spectral data as well as the melting point values of
compounds 2–10 were found to be comparable to the literature data.
General Procedure for the Synthesis of Hydroxy-3-arylcoumarins (2–10)
1st step. Acetoxy intermediates were synthesized under anhydrous conditions using material
previously dried at 60 ◦C for at least 12 h and at 300 ◦C for a few minutes immediately before
use. A solution containing anhydrous CH3CO2K (2.94 mmol), arylacetic acid (1.67 mmol), and the
corresponding hydroxybenzaldehyde (1.67 mmol) in Ac2O (1.2 mL) was refluxed for 16 h. The reaction
mixture was cooled, neutralized with 10% aqueous NaHCO3, and extracted with EtOAc (3 × 30 mL).
The organic layers were combined, washed with distilled water, dried (anhydrous Na2SO4), and
evaporated under reduced pressure. The product was purified by recrystallization in EtOH and dried
to afford the desired compound.
2nd step. Hydroxyl derivatives 2–10 were obtained by hydrolysis of their acetoxylated counterparts.
The appropriate acetoxylated coumarin, mixed with 2N aqueous HCl and MeOH, was refluxed for 3 h.
The resulting reaction mixture was cooled in an ice bath, and the reaction product, obtained as solid, was
filtered, washed with cold distilled water, and dried under vacuum to afford the desired compound.
List of synthesized compounds: 7,8-dihydroxy-3-phenylcoumarin 2 [26], 7,8-dihydroxy-3-
(3-hydroxyphenyl)coumarin 3 [28], 7,8-dihydroxy-3-(2-hydroxyphenyl)coumarin 4 [28], 3-(3,4-
dihydroxyphenyl)-7,8-dihydroxycoumarin 5 [28], 7,8-dihydroxy-3-(thiophen-3-yl)coumarin 6 [26],
3-(4-bromothiophen-2-yl)-7,8-dihydroxycoumarin 7 [29], 5,7-dihydroxy-3-phenylcoumarin 8 [30],
7-hydroxy-3-phenylcoumarin 9 [31], 8-hydroxy-3-phenylcoumarin 10 [30].
3.2. Biological Studies
3.2.1. Bacterial Cultures
The antibacterial activity of the tested compounds was evaluated using the following microbial
strains: Staphylococcus aureus ATCC 25923, methicillin-resistant S. aureus TN2A (MRSA strain belonging
to the collection of the Department of Medical Sciences and Public Health, University of Cagliari),
Bacillus cereus (B. cereus) ATCC 11178, Listeria monocytogenes (L. monocytogenes) ATCC 19115, Escherichia
coli (E. coli) ATCC 25922, Salmonella enterica serovar Enteritidis (S. Enteritidis) ATCC 13076, and
Pseudomonas aeruginosa (P. aeruginosa) ATCC 27853. All bacterial strains were stored on nutrient broth
(NB, Microbiol, Cagliari, Italy) plus 20% (v/v) glycerol at −20 ◦C. Before use, they were subcultured
twice in the appropriate medium. MICs and minimum bactericidal concentrations (MBCs) of the
compounds were determined by a broth microdilution method as previously described [32]. All tests
were performed with NB, and the compounds were dissolved in DMSO (5% v/v). Serial doubling
dilutions of each compound were performed in a 96-well microtiter plate in a final volume of 100 µL.
The final concentrations of the compounds ranged from 7.8 to 500µg/mL except for compound 8,
which was tested at concentrations ranging from 5.5 to 350 µg/mL. Overnight broth cultures were
prepared in NB and adjusted so that the final concentration in each well following inoculation was
approximately 5.0 × 105 cfu/mL. The concentration of each inoculum was confirmed using viable
counts on tryptic soy agar (TSA, Microbiol) plates. The controls included sterility of NB, sterility of
the compounds, control culture (inoculum), and control DMSO to check the effect of solvent on the
growth of microorganisms. Furthermore, ampicillin and gentamicin were used as positive control for
Gram-positive and Gram-negative bacteria, respectively. The MICs and MBCs were determined after
24 h incubation of the plates at 37 ◦C. Microbial growth was indicated by the presence of turbidity
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and a “pellet” on the well bottom. MICs were determined as the first well, in ascending order, which
did not produce a pellet. To confirm MICs and to establish MBCs, 10µL of broth were removed from
each well and inoculated on TSA plates. After incubation under the conditions described above, the
number of surviving microorganisms was determined. The MIC was the lowest concentration, which
resulted in a significant decrease in inoculum viability (> 90%), while the MBC was the concentration
where 99.9% or more of the initial inoculum was killed. All tests were conducted in triplicate and with
three replications, and the modal MIC and MBC values were selected.
3.2.2. Antioxidant Activity
The total free radical-scavenging capacity of compounds was determined by ABTS
[2,20-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)] method using 6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox) as standard, as previously described [33–35].
Briefly, the free radical ABTS was produced by reacting 7 mM ABTS with 2.45 mM potassium
persulfate (final concentration) in aqueous solution and kept in the dark at room temperature for 24 h
before use. Each compound (10 µL of an appropriate dilution) was added to 1 mL of ABTS, and the
absorbance was recorded at 734 nm after 1 min incubation. Results are expressed as EC50 values (µM),
calculated as concentration of compound that produces a 50% reduction in the original absorbance.
3.2.3. Statistical Analyses
Statistical differences were evaluated using GraphPad Prism software version 8 (San Diego,
CA, USA). Comparison between groups was assessed using one-way analysis of variance (one-way
ANOVA) followed by Tukey’s multiple comparison test. The values with p < 0.001 were considered
significant. Data are represented as mean ± SD of three independent experiments.
3.3. Computational Methodology
Docking Studies
The starting three-dimensional (3D) structure of S. aureus tyrosyl-tRNA synthetase (PDB id: 1JIJ)
and topoisomerase II DNA gyrase (PDB id: 2XCT) were obtained from the Protein Data Bank (PDB) [36].
Ligand molecules were sketched using the Marvin JS tool of ChemAxon (http://chemaxon.com). The
molecules were converted into 3D using open Babel software tool [37]. Before performing the
docking protocol, chemically correct models of the ligands were generated using the ligprep module
of Schrodinger, and the receptor structures were prepared using the Protein Preparation Wizard
Module [38]. Molecular docking was carried out using the Glide ligand docking module (Schrödinger
Release 2019-1: LigPrep, Schrödinger, LLC, New York, NY, 2019). Receptor grids were generated
using the Glide receptor grid generation module. Grids were generated for the prepared proteins.
For S. aureus gyrase complex, the grid was generated around ciprofloxacin, while for S. aureus TyrRS
complex, the grid was generated around SB-239629 ligand. The boundary box was at default value,
i.e., 14 Å × 14 Å × 14 Å, which was spacious enough to encompass the binding region. Further
details of the protocol employed have been described previously [39]. Docking between the S. aureus
tyrosyl-tRNA synthetase (PDB id: 1JIJ) protein structure and the ligands were also performed using
COACH-D server [40], which employs the Autodock Vina algorithm [41], as described previously [42].
For comparison, docking of the ligands was also performed on higher-resolution structure of S. aureus
tyrosyl-tRNA synthetase (PDB id: 1JIL) and topoisomerase II DNA gyrase (PDB id: 2XCS) (Figures S2
and S3, Supplementary Materials).
4. Conclusions
A family of 3-aryl/heteroarylcoumarins with structural features of flavonoids was synthesized
and studied for their antibacterial and antioxidant profiles. 3-Phenylcoumarin derivative 8, substituted
with hydroxyl groups at the 5 and 7 positions, showed the highest antibacterial activity against a
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panel of Gram-positive pathogens, including an MRSA strain, as well as an interesting antioxidant
profile. The presence of a phenyl ring at position 3 of the coumarin could be important as it is a
structural feature of the most active compound within the series. This compound could be considered
for its antibacterial potential and could be a valuable source for the design and development of new
anti-infective compounds. As the most active compound for further studies, docking studies on two
important targets were performed to elucidate a potential mechanism of action for this compound. Both
tyrosyl-tRNA synthetase and topoisomerase II DNA gyrase from S. aureus were studied as potential
targets, and a correlation between the observed inhibitory activity and the in silico molecular docking
scores of the best compound 8 was obtained. The importance of the 3-phenyl ring of compound 8 was
also corroborated by some of the aromatic–aromatic stacking interactions observed in the docking
studies. Moreover, compound 8 also exhibited druglikeness properties, leading us to consider 3-phenyl
hydroxycoumarins as a potential scaffold for improving antibacterial activity. Future studies will be
carried out to evaluate the antibiofilm activity of this compound and to explore the biological activities
of the metal complexes to find new compounds with increased antimicrobial potential and a broader
spectrum activity.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/15/2815/s1,
Figure S1: Validation of docking protocol. Ligand superimposition: co-crystal and docked conformations.
Figure S2: Docked conformation of the investigated ligands in (PDB id: 1JIL) Staphylococcus aureus tyrosyl-tRNA
synthetase protein structure. Figure S3: Docked conformation of the investigated ligands in (PDB id: 2XCS) S.
aureus Gyrase complex.
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